Cilostazol for peripheral arterial disease - a position paper from the Italian Society for Angiology and Vascular Medicine
Vasa. 2024 Mar 1. doi: 10.1024/0301-1526/a001114. Online ahead of print.ABSTRACT Cilostazol is a quinolinone-derivative selective phosphodiesterase inhibitor and is a platelet-aggregation inhibitor and arterial vasodilator for the symptomatic treatment of intermittent claudication (IC). Cilostazol has been shown to improve walking distance for patients with moderate to severe disabling intermittent claudication who do not respond to exercise therapy and who are not candidates for vascular surgical or endovascular procedures. Several studies evaluated the pharmacological effects of cilostazol for restenosis prevention and i...
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - March 1, 2024 Category: Surgery Authors: Romeo Martini Walter Ageno Corrado Amato Elisabetta Favaretto Angelo Porfidia Adriana Vison à Source Type: research
The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions
This study assesses the use and impact of cilostazol on patients undergoing PVI for peripheral arterial disease (PAD). (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - February 19, 2024 Category: Surgery Authors: Dana Alameddine, Fachreza Aryo Damara, Paula Pinto Rodriguez, Joshua Huttler, Martin D. Slade, Isibor Arhuidese, Edouard Aboian, Cassius Iyad Ochoa Chaar Tags: Clinical Research Source Type: research
Cilostazol-based dual antiplatelet treatment in ischemic stroke or transient ischemic attack patients with asymptomatic carotid artery disease: a propensity score matching analysis
ConclusionPatients with asymptomatic carotid artery stenosis who received cilostazol-based dual antiplatelet therapy had a lower risk of composite events but a higher risk of minor extracranial hemorrhage than those who received a single antiplatelet agent. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - February 15, 2024 Category: Neurology Source Type: research
Pharmacotherapy in SAH: Clinical Trial Lessons
CNS Neurol Disord Drug Targets. 2024 Jan 15. doi: 10.2174/0118715273251761231127095039. Online ahead of print.ABSTRACTSubarachnoid Haemorrhage (SAH) is a medical emergency with potentially devastating outcomes. It is without doubt that over the past decades, there has been a radical change in the approach towards patients with SAH, both in terms of the surgical as well as of the pharmacological treatments offered. The present review aims to outline the principal data regarding the best practice in the pharmacotherapy of SAH, as well as to sum up the emerging evidence from the latest clinical trials. To date, nimodipine is ...
Source: CNS and Neurological Disorders Drug Targets - January 20, 2024 Category: Drugs & Pharmacology Authors: Sotirios Apostolakis Pantelis Stavrinou Source Type: research
Cilostazol protects against degenerative cervical myelopathy injury and cell pyroptosis via TXNIP-NLRP3 pathway
Degenerative cervical myelopathy (DCM) is one of the most common and serious neurological diseases. Cilostazol has protective effects of anterior horn motor neurons and prevented the cell apoptosis. However, t... (Source: Cell Division)
Source: Cell Division - January 17, 2024 Category: Cytology Authors: Fei Xu, Zhuo Tian and Zhengguang Wang Tags: Research Source Type: research
The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease
Restenosis and late occlusion remain a significant problem for endovascular treatment of peripheral artery disease. This meta-analysis aims to evaluate the effect of cilostazol on late outcomes after endovascular repair of occlusive femoropopliteal disease. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - January 10, 2024 Category: Surgery Authors: George Galyfos, Alexandros Chamzin, Konstantinos Saliaris, Panagiotis Theodorou, Kyriaki Konstantinou, Frangiska Sigala, Konstantinos Filis Source Type: research
Giant negative T waves in an elder with generalized pain and weakness
A 72-year-old man with a history of hypertension and chronic kidney disease presented to our emergency department complaining of numbness in his arms and legs, diarrhea, generalized pain, and weakness for 10 days, which gradually worsened and made moving difficult. His medications included trichloromethiazide, azosemide, doxazosin, nifedipine, carvedilol, and cilostazol. Additionally, prednisone had been used to treat cholesterol embolisms in the toes. Approximately 1 month prior, osteoporosis due to chronic kidney disease and steroid use was suspected, and denosumab therapy and calcium replacement ware initiated. (Source:...
Source: The American Journal of Medicine - December 30, 2023 Category: General Medicine Authors: Yoshikazu Hirose, Nobuhiro Sato, Yasuo Hirose Tags: ECG image of the month Source Type: research
Giant Negative T Waves in an Elderly Patient with Generalized Pain and Weakness
A 72-year-old male with a history of hypertension and chronic kidney disease presented to our emergency department complaining of numbness in his arms and legs, diarrhea, generalized pain, and weakness for 10 days, which gradually worsened and made moving difficult. His medications included trichloromethiazide, azosemide, doxazosin, nifedipine, carvedilol, and cilostazol. Additionally, prednisone had been used to treat cholesterol embolisms in the toes. Approximately 1 month prior, osteoporosis due to chronic kidney disease and steroid use was suspected, and denosumab therapy and calcium replacement were initiated. (Source...
Source: The American Journal of Medicine - December 30, 2023 Category: General Medicine Authors: Yoshikazu Hirose, Nobuhiro Sato, Yasuo Hirose Tags: ECG image of the month Source Type: research
Cilostazol addition to aspirin may worsen the short-term outcome in patients with large artery disease: ADS subanalysis
Our previous acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of neurological deterioration in non-cardioembolic stroke patients. In this post-hoc analysis, we investigated whether the impact of dual antiplatelet therapy (DAPT) may depend on neurological severity, as represented by large artery disease. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - December 20, 2023 Category: Neurology Authors: Junya Aoki, Kazumi Kimura, on behalf of the ADS Investigators Source Type: research
Late-onset non-obstructive mesenteric ischemia (NOMI) resulting from delayed absorption of overdosed antihypertensive drugs: An autopsy case report
AbstractNon-obstructive mesenteric ischemia (NOMI) is caused by reduced blood flow to the intestines without physical occlusion in the mesenteric artery. Previous reports show that drug overdose occasionally induces late-onset NOMI; however, in most cases, the reason for the delayed onset is unclear. Here, we present an autopsy case of late-onset NOMI that was induced by a drug overdose. An 80-year-old man was admitted to the intensive care unit because of severe hypotension after an overdose of antihypertensive drugs. He received vasopressor therapy and continuous hemodiafiltration dialysis; however, gastrointestinal deco...
Source: Forensic Science, Medicine, and Pathology - December 19, 2023 Category: Forensic Medicine Source Type: research
Cilostazol plus Aspirin vs. Clopidogrel plus Aspirin in Acute Minor Stroke or Transient Ischemic Attack
CONCLUSIONS: The effectiveness and mortality of the two groups were similar for patients with acute minor ischemic stroke or TIA. However, cilostazol plus aspirin was associated with a higher risk of ICH compared to clopidogrel plus aspirin. Patients treated with cilostazol plus aspirin among this population should be monitored carefully to ensure their safety.PMID:38092384 | DOI:10.5551/jat.64502 (Source: Journal of Atherosclerosis and Thrombosis)
Source: Journal of Atherosclerosis and Thrombosis - December 13, 2023 Category: Cardiology Authors: Hsin-Yi Huang Jia-Hung Chen Nai-Fang Chi You-Chia Chen Source Type: research
